Why AstraZeneca May Dominate the Coronavirus Vaccine Market

Adria Cimino, The Motley Fool
·4-min read
Why AstraZeneca May Dominate the Coronavirus Vaccine Market

All eyes have been on the leaders in the coronavirus vaccine race these past few weeks. Pfizer and Moderna reported 95% efficacy and 94.5% efficacy, respectively. One dosing regimen in AstraZeneca's trial produced 90% efficacy -- but the average of its two tested dosing regimens only showed 70% efficacy.